Efficacy News and Research

RSS

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20, the company's novel enzyme-based treatment for malignant mesothelioma.

19 Mar 2011

Richmont obtains PURE's IV-7 Germ Defense disinfectant registration in South Africa

PURE Bioscience, creator of the patented silver dihydrogen citrate antimicrobial, today announced that its marketing partner, Richmont Sciences, LLC, through its distributor, Bio Care Products Ltd. of Lanseria, has obtained registration of PURE's SDC-based IV-7 Ultimate Germ Defense disinfectant for use on all inanimate surfaces by the South African National Regulator for Compulsory Specifications.

18 Mar 2011

Science journal publishes CYTK preclinical cardiac myosin activation research results

Cytokinetics, Incorporated announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart failure.

18 Mar 2011

KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction

KYTHERA Biopharmaceuticals, Inc. today presented additional efficacy data from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under the chin') fat. The expanded analysis focused on additional patient reported outcome measures, including instruments measuring submental fat impact, subject global assessments and subject self-ratings of chin attractiveness.

18 Mar 2011

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

18 Mar 2011

Researchers develop diagnostic test for motor neurone disease

NeuRA researchers are one step closer to developing a diagnostic test for motor neurone disease. Dr Steve Vucic, from Neuroscience Research Australia, says the test will allow people with motor neurone disease to be diagnosed up to eight months earlier than is currently possible.

17 Mar 2011

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.

17 Mar 2011

Nationwide observance raises awareness about HIV/AIDS spread in women

National Women and Girls AIDS Awareness Day, a nationwide observance that raises awareness and promotes action in the fight against HIV/AIDS, took place on March 10.

17 Mar 2011

pIMAGO nanopolymer can test cancer drug efficacy against biochemical processes

A Purdue University scientist's nanopolymer would make it easier and cheaper for drug developers to test the effectiveness of a widely used class of cancer inhibitors.

17 Mar 2011

Beike, ThermoGenesis enter agreement to employ new technology for stem cell therapies

Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced an agreement with USA-based ThermoGenesis Corp. to employ new, cutting edge stem cell processing and storage technology across its adult stem cell collection, processing, and archive platform.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Expert discusses certain measures that can help prevent HAI spread

Healthcare-associated infections represent a growing concern for both patients and healthcare providers across the nation. The Centers for Disease Control and Prevention estimates that approximately 1.7 million HAIs occur each year and contribute to the death of 99,000.

17 Mar 2011

Naltrexone may be effective in women with specific genetic variation

Results from a new study suggest that one of the most prescribed medications for alcohol dependence may be more effective in some people. Preliminary results show that naltrexone, one of the only medications approved for treating people with alcohol abuse problems, may only be effective in women and those with a specific genetic variation.

17 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

NAFC honors Florida's Cleveland Clinic physician with Continence Care Champion Award

The National Association For Continence awarded Gamal Ghoniem, MD, with the Rodney Appell Continence Care Champion Award at the Society for Urodynamics and Female Urology Awards Reception on March 4, held during the 2011 SUFU Winter Meeting in Phoenix, AZ.

16 Mar 2011

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

The Montreal Heart Institute today announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis REgression?) study of CER-001 in patients with acute coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases.

16 Mar 2011

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC).

16 Mar 2011

Gadavist approved by FDA for use in central nervous system MRI scans

The U.S. Food and Drug Administration approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system.

16 Mar 2011

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.

16 Mar 2011

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

Argon Medical Devices, Inc. announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an implantable device used in the prevention of Pulmonary Embolism (PE).

15 Mar 2011

Efficacy News and Research

Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma

Richmont obtains PURE's IV-7 Germ Defense disinfectant registration in South Africa

Science journal publishes CYTK preclinical cardiac myosin activation research results

KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

Researchers develop diagnostic test for motor neurone disease

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

Nationwide observance raises awareness about HIV/AIDS spread in women

pIMAGO nanopolymer can test cancer drug efficacy against biochemical processes

Beike, ThermoGenesis enter agreement to employ new technology for stem cell therapies

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

Expert discusses certain measures that can help prevent HAI spread

Naltrexone may be effective in women with specific genetic variation

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

NAFC honors Florida's Cleveland Clinic physician with Continence Care Champion Award

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

Gadavist approved by FDA for use in central nervous system MRI scans

Enzo Life Sciences introduces ELISA system to detect SMN protein

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News